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OBJECTIVE—Genome-wide association studies have begun to
elucidate the genetic architecture of type 2 diabetes. We exam-
ined whether single nucleotide polymorphisms (SNPs) identiﬁed
through targeted complementary approaches affect diabetes in-
cidence in the at-risk population of the Diabetes Prevention
Program (DPP) and whether they inﬂuence a response to pre-
ventive interventions.
RESEARCH DESIGN AND METHODS—We selected SNPs
identiﬁed by prior genome-wide association studies for type 2
diabetes and related traits, or capturing common variation in 40
candidate genes previously associated with type 2 diabetes,
implicated in monogenic diabetes, encoding type 2 diabetes drug
targets or drug-metabolizing/transporting enzymes, or involved
in relevant physiological processes. We analyzed 1,590 SNPs for
association with incident diabetes and their interaction with
response to metformin or lifestyle interventions in 2,994 DPP
participants. We controlled for multiple hypothesis testing by
assessing false discovery rates.
RESULTS—We replicated the association of variants in the
metformin transporter gene SLC47A1 with metformin response
and detected nominal interactions in the AMP kinase (AMPK)
gene STK11, the AMPK subunit genes PRKAA1 and PRKAA2,
and a missense SNP in SLC22A1, which encodes another met-
formin transporter. The most signiﬁcant association with diabe-
tes incidence occurred in the AMPK subunit gene PRKAG2
(hazard ratio 1.24, 95% CI 1.09–1.40, P  7  10
4). Overall, there
were nominal associations with diabetes incidence at 85 SNPs
and nominal interactions with the metformin and lifestyle inter-
ventions at 91 and 69 mostly nonoverlapping SNPs, respectively.
The lowest P values were consistent with experiment-wide 33%
false discovery rates.
CONCLUSIONS—We have identiﬁed potential genetic determi-
nants of metformin response. These results merit conﬁrmation in
independent samples. Diabetes 59:2672–2681, 2010
T
he number of common genetic variants repro-
ducibly associated with type 2 diabetes is
growing (1). Well-powered candidate gene asso-
ciation studies and, more recently, genome-wide
association studies (GWASs) have identiﬁed over two
dozen loci robustly and reproducibly associated with type
2 diabetes or related quantitative glycemic traits. While
these discoveries have advanced our understanding of the
genetics of type 2 diabetes, they only explain a small
fraction of the overall genetic contribution to the disease.
Furthermore, in most cases, the genes involved in type 2
diabetes risk have not yet been identiﬁed: the majority of
the associations detected thus far merely mark genomic
regions where a certain variant is overrepresented in
diseased cases versus unaffected controls, and subsequent
ﬁne-mapping and functional studies are necessary before a
molecular mechanism can be ascribed to each locus.
Nevertheless, progress in the translation of genetic
discoveries to clinical practice can advance along parallel
paths. On the one hand, knowledge of the speciﬁc gene or
variant causing the molecular phenotype is not needed to
determine whether the associated region can aid predic-
tion or affect the response to therapy; and on the other
hand, targeted approaches can be applied in vivo in
humans that shed light on the function of genes of interest,
as a way to narrow the regions to study. These two
objectives can be achieved by controlled interventions in
randomized clinical trials. Such pharmacogenetic or gene-
environmental strategies can fulﬁll both complementary
roles, testing whether genetic variants predict response to
therapy and whether a particular pharmacologic or life-
style intervention affects the mode of action of speciﬁc
risk loci.
In type 2 diabetes, the ﬁeld of pharmacogenetics re-
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tion has yielded clinically actionable results in neonatal
diabetes and maturity-onset diabetes of the young, extend-
ing these studies to common type 2 diabetes has been
more arduous (2). With regard to metformin, intriguing
results were obtained by Shu et al. (3) in their investigation
of common variants in SLC22A1, which encodes the
liver-speciﬁc organic cation transporter 1 responsible for
the absorption of metformin into hepatocytes: in a study of
20 human participants, carriers of reduced-function poly-
morphisms of SLC22A1 had a 17% higher area under the
glucose curve after an oral glucose tolerance test when
treated with metformin, indicating decreased responsive-
ness. Unfortunately, these results have not been conﬁrmed
in the long-term follow-up of a large observational cohort
of patients treated with metformin monotherapy (4). Re-
cently, a preliminary association was discovered between
a variant in SLC47A1, which encodes the multidrug and
toxin extrusion protein 1 (involved in the excretion of
metformin into the bile and urine) and the glucose-lower-
ing effect of metformin (5).
The Diabetes Prevention Program (DPP) can help an-
swer some of these questions (6). The strengths of this
randomized clinical trial include its enrollment of partici-
pants at high risk of developing diabetes, multiethnic
composition, comprehensive longitudinal measures, and
standardized behavioral and pharmacologic interventions.
Extensive in-depth phenotyping and the use of behavioral
and pharmacologic interventions allow characterization of
the effects of known type 2 diabetes variants on diabetes
incidence and response to therapy. We therefore designed
a large-scale genotyping study by which we tested 1,590
variants identiﬁed through prior genetic studies of type 2
diabetes or related traits, as well as those capturing all
common variation in 40 biological candidate genes, for
association with diabetes incidence or response to preven-
tive interventions (lifestyle modiﬁcation or metformin) in
the DPP.
RESEARCH DESIGN AND METHODS
The DPP. The DPP was a 27-center randomized clinical trial in the U.S. that
assessed whether metformin or lifestyle interventions prevent or delay
development of diabetes in high-risk individuals. The DPP enrolled 3,234
overweight or obese people without diabetes but with impaired glucose
tolerance and elevated fasting glucose and randomized them to placebo,
metformin (850 mg twice daily), or a lifestyle intervention program consisting
of individual and group counseling sessions conducted by dietary and exercise
professionals aimed at 7% weight loss and 150 min of physical activity per
week. A fourth arm of 585 subjects assigned to troglitazone (400 mg daily) was
stopped because of hepatotoxicity (7). The primary end point was develop-
ment of diabetes, ascertained by semi-annual measurement of fasting glucose
or an annual 75-g oral glucose tolerance test, either of which was conﬁrmed
on a second occasion. The metformin and lifestyle interventions reduced the
incidence of diabetes by 31% (95% CI 17–43) and 58% (95% CI 48–66),
respectively, versus placebo (6). The 2,994 participants in the placebo,
metformin, and lifestyle arms who gave informed consent for genetic inves-
tigation are the subjects of this study, which was approved by institutional
review boards at each of the 27 participating sites. Their demographic
characteristics are shown in Table 1.
SNP selection. We selected SNPs in two ways: 1) SNPs in high-likelihood
candidate genes and 2) SNPs identiﬁed by ongoing GWASs for type 2 diabetes
or related metabolic traits. The 40 candidate genes were tentatively associated
with type 2 diabetes, implicated in monogenic forms of diabetes, known to
encode type 2 diabetes drug targets or drug-metabolizing/transporting en-
zymes, or involved in cellular metabolism, hormonal regulation, or response
to exercise (Table 2). We used Tagger (8) to capture (at r
2  0.8) all common
(minor allele frequency 5%) variations in European (CEU) and African (YRI)
HapMap populations in these candidate genes. For seven additional genes
(ACE, CASQ1, GCKR, IRS1, KCNQ1, LIPC, and NOS3), rather than attempting
full coverage of genetic variation, we selected a limited number of SNPs
previously associated with the phenotypes of interest. As the study evolved, it
became obvious that previous reports of genetic association provided an
equally compelling—or perhaps even higher—prior probability of true asso-
ciation with type 2 diabetes traits than biological function alone; thus, we also
focused on GWASs whose results were available at the time this custom-
made genotyping array was designed: SNPs associated with type 2 diabetes
in the Diabetes Genetics Initiative (9), DIAGRAM (10), or three smaller
100K SNP GWASs in which we participated (11–13); SNPs tentatively
associated with quantitative glycemic traits (fasting glucose, the insulino-
genic index, and insulin resistance by homeostasis model assessment) in
the Diabetes Genetics Initiative; or SNPs associated with obesity (14,15) or
lipid traits (16–18). For quality control and analytical reasons, we also
included some SNPs previously genotyped in these samples, as well as
TABLE 1
Baseline characteristics of the DPP participants enrolled in the genetic study
Overall Placebo Metformin Lifestyle
n 2,994 1,000 990 1,004
Sex
Male 982 (32.8) 311 (31.1) 344 (34.7) 327 (32.6)
Female 2,012 (67.2) 689 (68.9) 646 (65.3) 677 (67.4)
Race or ethnic group
White 1,674 (55.9) 557 (55.7) 570 (57.6) 547 (54.5)
African American 612 (20.4) 210 (21.0) 206 (20.8) 196 (19.5)
Hispanic 498 (16.6) 164 (16.4) 158 (16.0) 176 (17.5)
Asian/Paciﬁc Islander 128 (4.3) 39 (3.9) 33 (3.3) 56 (5.6)
American Indian 82 (2.7) 30 (3.0) 23 (2.3) 29 (2.9)
Family history of diabetes 2,089 (69.8) 703 (70.4) 683 (69.0) 703 (70.1)
History of gestational diabetes mellitus 321 (16.0) 105 (15.2) 104 (16.1) 112 (16.5)
Quantitative traits
Age (years) 50.8  10.7 50.5  10.5 51.0  10.4 50.7  11.4
Weight (kg) 94.6  20.3 94.8  20.2 94.6  20.0 94.5  20.8
BMI (kg/m
2) 34.1  6.7 34.3  6.7 34.0  6.7 34.0  6.8
Waist circumference (cm) 105.2  14.6 105.3  14.5 105.0  14.6 105.3  14.9
Waist-to-hip ratio 0.92  0.09 0.92  0.08 0.93  0.09 0.93  0.09
Plasma glucose (mg/dl)
In the fasting state 106.7  8.2 107.0  8.4 106.7  8.4 106.5  7.9
2 h after an oral glucose load 164.7  17.1 164.6  17.2 165.1  17.2 164.4  16.9
Glycated hemoglobin (%) 5.91  0.51 5.91  0.50 5.91  0.51 5.91  0.51
Leisure physical activitiy (MET h/week) 16.1  25.9 16.6  29.1 16.4  25.9 15.4  22.4
Data are n (%) or means  SD.
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ancestry in African American (19) or Hispanic (20) participants. Finally, we
included a small number of SNPs provided by investigators leading
ancillary studies approved by the DPP ancillary studies and genetics
subcommittees. The total number of SNPs analyzed for each category is
shown in Table 2.
Genotyping. We initially designed a 1,536-SNP oligonucleotide pool array for
the Illumina BeadArray platform (Illumina, San Diego, CA). In the 1,445 SNPs
that passed quality control metrics, the sample pass rate was 99.8% and the
average genotyping call rate per SNP was 98.5%. Because 91 SNPs failed
genotyping on the oligonucleotide pool array, we assessed the adequacy of the
coverage afforded by the successfully genotyped SNPs in each region. To
rescue relevant SNPs, we used linkage disequilibrium (LD) to select proxy
SNPs highly correlated to those that had failed and genotyped them on a
Sequenom iPLEX platform. After quality control, 1,590 SNPs were available
for analysis.
Statistical analysis. We tested the effect of each SNP on diabetes incidence
under an additive genetic model by Cox proportional hazards models, using
age, sex, ethnicity, and treatment arm as covariates and including treatment
(metformin or lifestyle)  genotype interaction terms. In secondary analyses,
we stratiﬁed participants by treatment arm; if the interaction P value was
nominally signiﬁcant, only stratiﬁed analyses were considered. We used the
MACH software (21) and the HapMap CEU population to impute allelic calls
at SNPs not directly genotyped in the DPP. Because of concerns regarding the
accuracy of imputation methods in admixed populations, we restricted this
procedure to individuals of self-described non-Hispanic white ethnicity.
Genotype-phenotype correlations on imputed data were considered conﬁrma-
tory of prior associations, as well as an initial ﬁne-mapping exploration. Using
the program STRUCTURE (22), we applied these markers trained on the
HapMap populations to assign a proportion of global European ancestry to
each DPP participant.
We considered two sequential approaches to correct for multiple hypoth-
esis testing based on the number of SNPs examined (23). We ﬁrst ran 1,000
permutations in which diabetes outcome was randomly assigned to an
individual’s genotype within each ethnicity and treatment group (keeping sex
and age together with genotype, and BMI with diabetes outcome). The P value
for the overall null hypothesis is the fraction of permutations (n/1,000) for
which the scalar statistic is at least as extreme as that observed for the data
(24). To estimate the expected proportion of type I errors among the rejected
hypotheses, we also computed false discovery rates (FDRs) as in Benjamini
and Hochberg (25).
RESULTS
Supplementary Table 1 (available in an online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db10-
0543/DC1) shows that we achieved adequate coverage of
all 40 genes in the two targeted populations, with 37 genes
reaching at least 80% of common variants captured at r
2 
0.8 in Europeans and all 40 reaching at least 70% of
common variants captured at that level (comparable num-
bers were obtained in Africans). The average proportion of
European ancestry among the DPP self-described white
participants, as determined by ancestry-informative mark-
ers, was 98.9%, and the average proportion of West-African
ancestry among DPP self-described African American par-
ticipants was 89.3%. Given these results, we used self-
described ethnicity as a covariate for these analyses. The
full set of results is available in supplementary Table 2.
Table 3 shows the candidate gene regions harboring
variants nominally associated with diabetes incidence in
the treatment-adjusted models for the full study (i.e., there
was no evidence for interaction with either intervention);
only the top SNP within each gene region (out of 85
nominal associations) is given. The most signiﬁcant asso-
ciations occurred at SNPs in the AMP kinase (AMPK)
subunit gene PRKAG2 (hazard ratio [HR] 1.24, 95% CI
1.09–1.40, P  7.0  10
4 for the top SNP rs5017427,
which is consistent with an experiment-wide 34% FDR).
Twelve other PRKAG2 SNPs were nominally associated
with diabetes (ﬁve in the top ten). Although most of them
are in moderate to high LD with the index SNP (r
2 ranging
from 0.49 to 1.0 in HapMap CEU), at least two of them
(rs954482 and rs2727537) are only weakly correlated with
rs5017427 (r
2 0.07 and 0.05, respectively). Nevertheless,
the consistency of the association signal in this region
provides reassurance with regard to the absence of geno-
typing artifacts in our dataset. Of SNPs previously associ-
ated with type 2 diabetes in the 100K Amish, Framingham,
or Pima GWASs, three (rs1422930 in ODZ2, rs1859441 near
COL2A1 and SENP1, and rs385909 near SH3YL1) had
consistent nominal associations with diabetes incidence in
the DPP, and two had nominally signiﬁcant associations
(rs10520926 and rs3136279) in the opposite direction. On
the other hand, none of the six SNPs selected from the
TABLE 2
Number of SNPs analyzed per selection category
Category n
Candidate genes (n SNPs) 1,256
Comprehensive coverage 1,241
Monogenic diabetes 317
ABCC8 (84), GCK (37), HNF1A (20), HNF1B (74),
HNF4A (66), KCNJ11 (9), NEUROD1 (14), PDX1
(13)
Monogenic obesity 21
MC4R (21)
Previously associated with type 2 diabetes 60
CAPN10 (33), PTPN1 (27)
Drug targets 190
PPARG (59), PRKAA1 (9), PRKAA2 (18), PRKAB1
(10), PRKAB2 (13), PRKAG1 (7), PRKAG2 (53),
PRKAG3 (11), STK11 (10)
Drug-metabolizing enzymes and transporters 135
CYP3A4 (15), SLC22A1 (47), SLC22A2 (44),
SLC47A1 (29)
Hormonal regulation 117
ADIPOQ (25), ADIPOR1 (22), ADIPOR2 (31), GCG
(13), ITLN1 (11), ITLN2 (15)
Cellular energy 334
FOXO1A (35), PCK1 (37), PCK2 (14), PKLR (10),
PPARA (63), PPARGC1A (79), PPARGC1B (96)
Response to exercise 67
CREB1 (13), MEF2A (38), MEF2D (16)
Select SNPs in candidate genes 15
ACE (1), CASQ1 (2), GCKR (2), IRS1 (2), KCNQ1
(1), LIPC (1), NOS3 (6)
Ancillary studies 26
ALOX5 (15), IL6 (1), renin-angiotensin system (7),
USF1 (2), TNF (1)
GWASs 248
Amish 100K GWAS (13): Type 2 diabetes 46
Framingham Heart Study 100K GWAS (11): Type 2
diabetes 38
Pima 100K GWAS (12): Type 2 diabetes 12
Obesity (14,15) 11
Diabetes Genetics Initiative (9)
Fasting glucose 37
Insulin resistance by homeostasis model assessment 16
Insulinogenic index 17
Type 2 diabetes 30
DIAGRAM (10): Type 2 diabetes 6
Lipids (16–18) 35
Quality control 60
African American ancestry informative markers (19) 29
Hispanic ancestry informative markers (20) 29
Previously genotyped in DPP 2
Total 1,590
CANDIDATE GENES IN THE DPP
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from 1.05 to 1.15) were nominally signiﬁcant in the DPP.
Fifteen SNPs in genes that cause either maturity-onset
diabetes of the young or neonatal diabetes were nominally
associated with diabetes incidence; one of them,
rs11868513 in HNF1B (not in LD with the previously type
2 diabetes–associated SNP rs757210), was strongly asso-
ciated with diabetes incidence in the placebo arm (HR
1.69, 95% CI 1.36–2.10, P  2  10
6). Finally, 14 SNPs in
genes that encode metformin transporters (SLC22A1,
SLC22A2, and SLC47A1) were nominally associated with
diabetes incidence. Of the 85 nominal associations with
diabetes incidence in DPP, only two SNPs (rs651164 in
SLC22A1 and rs3736265 in PPARGC1A) were nominally
associated with type 2 diabetes in DIAGRAM in a
consistent direction (OR 1.08, 95% CI 1.02–1.16, P 
0.01, and OR 1.15, 95% CI 1.01–1.31, P  0.04, respec-
tively), with 60 other SNPs not being nominally signiﬁ-
cantly associated in DIAGRAM and 23 SNPs not
captured in that dataset.
Table 4 shows the candidate gene regions harboring
variants that have a nominally signiﬁcant genotype 
metformin interaction; only the top SNP within each gene
region is given (out of 91 nominal associations). The best
result was consistent with a study-wide 33% FDR. At
rs8065082 in SLC47A1, there was a nominal interaction
with metformin (P  0.006), with the minor allele associ-
ated with lower diabetes incidence in the metformin arm
(HR 0.78, 95% CI 0.64–0.96, P  0.02) but not in the
placebo arm (1.15, 0.97–1.37, P  0.11). At this locus,
major allele homozygotes did not beneﬁt from metformin
with regard to diabetes prevention (HR 1.07, 95% CI
0.77–1.50, vs. placebo, P  0.68), whereas minor allele
carriers did (0.58, 0.46–0.73, vs. placebo, P  0.001; Fig. 1).
We also noted a nominally signiﬁcant interaction of a
missense SNP in SLC22A1 (rs683369, encoding L160F)
with metformin, with the major allele protecting from
diabetes in the metformin arm (HR 0.69, 95% CI 0.53–0.89,
P  0.004) but not the placebo arm (1.01, 0.79–1.30, P 
0.91); the major allele is therefore associated with 31% risk
reduction in diabetes incidence but only under the action
of metformin. In this arm, the likelihood of developing
diabetes depended on the number of phenylalanine al-
leles (HR 0.72, 95% CI 0.59–0.88, vs. placebo for LL
homozygotes; 0.92, 0.66–1.28, for heterozygotes; and
1.44, 0.56–3.67, for FF homozygotes). There were ﬁve
nominally signiﬁcant interactions at SNPs encoding
putative drug targets for metformin, in the gene encod-
ing the AMPK kinase STK11 and the AMPK subunit
genes PRKAA1, PRKAA2, and PRKAB2, respectively. A
total of 22 SNPs in the ABCC8-KCNJ11 region also had
nominally signiﬁcant interactions with metformin, in-
cluding rs5215, which is tightly linked to the widely
replicated type 2 diabetes–associated missense SNP
rs5219 (E23K) in KCNJ11.
Table 5 shows the candidate gene regions harboring
variants that have a nominally signiﬁcant interaction with
the lifestyle intervention; only the top SNP within each
gene region is given (out of 69 nominal associations). The
best result was consistent with an experiment-wide 84%
FDR. Twelve of the top ﬁndings were in four AMPK
subunit genes (PRKAA2, PRKAB2, PRKAG1, and
PRKAG2), and 11 SNPs clustered around the peroxisome
proliferator–associated receptor  coactivators 1 and 1	
(PPARGC1A and PPARGC1B, respectively).
Review of 1,609 SNPs imputed in non-Hispanic white
DPP participants (supplementary Table 3) revealed the
nominal association of other PRKAG2 SNPs with diabetes
incidence (best P  5  10
5). Imputed SNPs in the
PRKAA1, PRKAA2, and ABCC8-KCNJ11 regions also had
nominally signiﬁcant interactions with metformin.
DISCUSSION
We conducted a large-scale genotyping study in the DPP,
with the aim to test whether common variants in candidate
genes involved in major spheres of human physiology
predict diabetes incidence or response to preventive inter-
ventions in a multiethnic at-risk population. Our second-
ary purpose was to characterize the mechanism of action
of previously associated variants. We provide evidence
supporting a previously reported association of variants in
the metformin transporter gene SLC47A1 with weaker
metformin response, here deﬁned as the reduced ability of
metformin to lower diabetes incidence (5). We identiﬁed a
number of nominal associations with diabetes incidence
or metformin response in several compelling candidate
genes; however, none stand strict statistical correction for
multiple hypothesis testing by FDRs.
Correction for multiple tests requires careful consider-
ation in genetic association studies (26). When large
numbers of SNPs are tested, methods that are valid in the
presence of correlations due to LD, such as permutation
methods or evaluation of FDR, are preferred over those
that assume independence of SNPs. The scope of the
present analysis is guided by technological convenience,
and it might be argued that the number of distinct scien-
tiﬁc hypotheses formulated, rather than the physical size
of the genotyping array, is most relevant to the interpre-
tation of results. However, what constitutes a single hy-
pothesis (e.g., an SNP, a gene, an entire pathway, or a
constellation of phenotypes) is subjective. On the other hand,
correcting for the equivalent of the universe of independent
common variants in the human genome (empirically esti-
mated at 
1 million [27]) is gaining increasing favor among
genetic statisticians. In this context, the novel ﬁndings re-
ported here should be viewed as hypothesis-generating.
We previously quantiﬁed the power of the DPP to detect
modest genetic effects on diabetes incidence (28). Assum-
ing there are no gene-treatment interactions, these calcu-
14
Placebo Metformin Lifestyle
CC CT TT
C
a
s
e
s
/
1
0
0
 
p
e
r
s
o
n
-
y
e
a
r
s 12
10
8
6
4
2
0
FIG. 1. Diabetes incidence in the DPP, by genotype at rs8065082 in the
SLC47A1 gene. This SNP is in tight LD with rs2289669 (r
2 
0.8), whose
major allele predicts a poorer response to metformin (5). In the DPP,
major allele homozygotes at rs8065082 did not beneﬁt from metformin
with regard to diabetes prevention, whereas minor allele carriers did
(P < 0.001).
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detect a previously reported effect size of 
20% for an SNP
of 10% frequency at an  level of 0.05, while the placebo,
lifestyle modiﬁcation, and metformin arms have 53, 34,
and 44% power, respectively. The DPP has inadequate
power for detecting an effect size of 10%. Thus, it is not
TABLE 3
Candidate gene variants nominally associated with diabetes incidence in the DPP
Overall, treatment-adjusted
SNP Chromosome
Position
(NCBI 36) Gene
Alleles
(m/M)
HR
(95% CI)
Observed
P
Permuted
P FDR Q
rs5017427 7 150886136 PRKAG2 T/C 1.24 (1.09–1.40) 0.0007 0.001 0.34
rs2453583 17 19382628 SLC47A1 T/A 0.81 (0.72–0.92) 0.001 0.003 0.34
rs315978 6 160572848 SLC22A2 T/C 0.73 (0.60–0.89) 0.002 0.002 0.34
rs4273018 15 97910079 MEF2A T/C 1.20 (1.07–1.35) 0.002 0.005 0.50
rs9551419 13 27378356 PDX1 T/C 0.77 (0.65–0.92) 0.004 0.003 0.34
rs1042531 20 55574386 PCK1 C/A 0.84 (0.74–0.94) 0.004 0.002 0.34
rs1342387 1 201180979 ADIPOR1 A/G 1.17 (1.05–1.31) 0.006 0.009 0.55
rs1388332 4 23438412 PPARGC1A G/A 1.32 (1.08–1.61) 0.006 0.007 0.53
rs6093976 20 42469194 HNF4A A/G 0.78 (0.65–0.94) 0.008 0.008 0.53
rs651164 6 160501364 SLC22A1 T/C 1.18 (1.04–1.33) 0.008 0.007 0.53
rs12330015 22 44968942 PPARA C/T 0.79 (0.66–0.95) 0.01 0.01 0.58
rs2755209 13 40035804 FOXO1 C/A 1.16 (1.04–1.31) 0.01 0.01 0.58
rs10875552 5 149169682 PPARGC1B C/T 0.84 (0.74–0.96) 0.01 0.008 0.53
rs739690 11 17373454 KCNJ11 C/G 1.87 (1.15–3.05) 0.01 0.01 0.66
rs7811022 7 99223619 CYP3A4 G/C 1.33 (1.06–1.67) 0.01 0.02 0.67
rs832646 2 182266649 NEUROD1 C/T 0.57 (0.35–0.91) 0.02 0.02 0.68
rs11836547 12 1756708 ADIPOR2 C/G 1.37 (1.05–1.78) 0.02 0.02 0.67
rs916829 11 17397049 ABCC8 A/G 0.80 (0.66–0.97) 0.03 0.04 0.78
rs12951345 17 33151976 HNF1B G/T 1.17 (1.02–1.34) 0.03 0.03 0.73
rs709159 3 12456203 PPARG C/A 1.16 (1.01–1.33) 0.04 0.04 0.82
rs12058717 1 159108473 ITLN1 T/C 1.28 (1.01–1.63) 0.04 0.049 0.87
SNPs in or near biological candidate genes showing nominal association with diabetes incidence in the DPP are shown. HRs are estimated
for the minor allele (m) vs. the major allele (M) under an additive genetic model. Only the top SNP within each gene region is shown; the full
set of results (including allele frequencies) is available in supplementary Table 2.
TABLE 4
Candidate gene variants showing a nominally signiﬁcant interaction with the metformin intervention in the DPP
SNP Chromosome
Position
(NCBI 36) Gene
Alleles
(m/M)
Interaction genotype * metformin
Observed
P
Permuted
P FDR Q
rs11868513 17 33126805 HNF1B A/G 0.0007 0.001 0.33
rs4148609 11 17441307 ABCC8 A/G 0.002 0.002 0.33
rs11086926 20 42492111 HNF4A G/T 0.002 0.001 0.33
rs10213440 4 23475437 PPARGC1A C/T 0.002 0.002 0.33
rs4424892 15 97921908 MEF2A G/A 0.003 0.006 0.38
rs8065082 17 19405783 SLC47A1 T/C 0.006 0.008 0.41
rs6666307 1 154719358 MEF2D T/A 0.009 0.005 0.38
rs3792269 2 241180152 CAPN10 G/A 0.01 0.01 0.41
rs758027 12 1662034 ADIPOR2 C/T 0.01 0.002 0.33
rs7124355 11 17369536 KCNJ11 A/G 0.01 0.01 0.41
rs662301 6 160616909 SLC22A2 T/C 0.02 0.02 0.47
rs2908289 7 44190467 GCK A/G 0.02 0.02 0.47
rs741765 19 1172545 STK11 T/C 0.02 0.02 0.47
rs6701920 1 159181541 ITLN2 A/G 0.02 0.01 0.41
rs741579 5 149165563 PPARGC1B G/A 0.02 0.01 0.38
rs4810083 20 55553677 PCK1 T/C 0.03 0.03 0.53
rs9803799 1 56952660 PRKAA2 G/T 0.03 0.02 0.49
rs17367421 1 153553865 PKLR C/G 0.03 0.03 0.53
rs683369 6 160471194 SLC22A1 G/C 0.03 0.03 0.53
rs249429 5 40817996 PRKAA1 C/T 0.04 0.03 0.53
rs6733736 2 162704406 GCG G/A 0.04 0.01 0.43
rs4253652 22 44947503 PPARA G/A 0.04 0.02 0.47
rs6690158 1 145123867 PRKAB2 T/C 0.04 0.03 0.53
SNPs in or near biological candidate genes showing a nominally signiﬁcant interaction with the metformin intervention in the DPP are shown.
HRs are estimated for the minor allele (m) vs. the major allele (M) under an additive genetic model. Only the top SNP within each gene region
is shown; the full set of results (including allele frequencies) is available in supplementary Table 2.
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derived ﬁndings in that range or that it fails to reach
genome-wide signiﬁcance in discovery efforts. Our null
results on diabetes incidence for truly associated variants
may be due to the high-risk population at baseline, the
short time of follow-up (3.2 years on average), and/or the
use of interventions effective in reducing diabetes inci-
dence. On the other hand, considering the number of
variants likely to inﬂuence the phenotypes under study,
even submaximal power is likely to provide a number of
true positive associations. In this context, genotyped and
imputed SNPs in the gene encoding the AMPK 2 subunit
(PRKAG2) merit further consideration. While the associa-
tion of SNPs in genes that encode metformin transporters
with type 2 diabetes in the entire DPP cohort (if real)
requires explanation, this could be due to a sufﬁciently
TABLE 3
Continued
Placebo Metformin Lifestyle
HR (95% CI)
Observed
P HR (95% CI)
Observed
P HR (95% CI)
Observed
P
1.26 (1.04–1.53) 0.02 1.15 (0.93–1.42) 0.20 1.34 (1.05–1.71) 0.02
0.84 (0.70–1.02) 0.08 0.68 (0.54–0.86) 0.001 0.94 (0.73–1.21) 0.65
0.75 (0.57–1.00) 0.05 0.67 (0.47–0.96) 0.03 0.74 (0.49–1.11) 0.14
1.20 (1.00–1.44) 0.05 1.37 (1.11–1.67) 0.003 0.96 (0.76–1.23) 0.76
0.77 (0.59–1.00) 0.05 0.85 (0.63–1.14) 0.27 0.67 (0.45–1.00) 0.05
0.83 (0.69–1.00) 0.05 0.98 (0.80–1.20) 0.85 0.64 (0.49–0.84) 0.001
1.22 (1.02–1.45) 0.03 1.07 (0.88–1.30) 0.51 1.24 (0.99–1.56) 0.07
1.17 (0.85–1.60) 0.33 1.33 (0.94–1.88) 0.10 1.51 (1.03–2.21) 0.03
0.76 (0.57–1.00) 0.05 0.85 (0.62–1.16) 0.31 0.75 (0.51–1.10) 0.14
1.08 (0.90–1.30) 0.39 1.14 (0.92–1.42) 0.23 1.40 (1.09–1.78) 0.01
0.82 (0.63–1.07) 0.15 0.78 (0.57–1.08) 0.14 0.72 (0.49–1.06) 0.10
1.05 (0.89–1.25) 0.56 1.29 (1.05–1.58) 0.02 1.25 (0.97–1.60) 0.08
0.91 (0.75–1.12) 0.37 0.89 (0.72–1.11) 0.32 0.65 (0.48–0.86) 0.003
1.16 (0.48–2.79) 0.74 2.66 (1.33–5.31) 0.01 2.23 (0.76–6.56) 0.15
1.16 (0.81–1.65) 0.42 1.99 (1.38–2.87) 0.0002 0.95 (0.56–1.60) 0.84
0.59 (0.31–1.13) 0.11 0.79 (0.37–1.72) 0.56 0.24 (0.06–1.01) 0.05
1.60 (1.09–2.34) 0.02 0.92 (0.56–1.52) 0.75 1.72 (1.00–2.95) 0.05
0.76 (0.56–1.02) 0.06 0.89 (0.63–1.25) 0.50 0.78 (0.52–1.16) 0.21
1.13 (0.91–1.40) 0.27 1.20 (0.95–1.52) 0.12 1.20 (0.91–1.59) 0.20
1.06 (0.86–1.31) 0.56 1.21 (0.95–1.56) 0.13 1.27 (0.96–1.68) 0.09
1.24 (0.89–1.74) 0.20 1.35 (0.87–2.09) 0.18 1.32 (0.77–2.28) 0.31
TABLE 4
Continued
Placebo Metformin Lifestyle
HR (95% CI)
Observed
P HR (95% CI)
Observed
P HR (95% CI)
Observed
P
1.69 (1.36–2.10) 0.000002 0.87 (0.65–1.16) 0.33 1.08 (0.79–1.47) 0.64
1.24 (1.04–1.48) 0.02 0.79 (0.63–0.98) 0.03 1.06 (0.83–1.37) 0.64
0.82 (0.61–1.11) 0.20 1.81 (1.35–2.43) 0.0001 1.29 (0.91–1.83) 0.15
0.76 (0.59–0.97) 0.03 1.31 (1.03–1.66) 0.03 1.07 (0.80–1.43) 0.65
0.88 (0.72–1.09) 0.24 1.43 (1.14–1.80) 0.002 0.78 (0.58–1.05) 0.10
1.15 (0.97–1.37) 0.11 0.78 (0.64–0.96) 0.02 1.09 (0.86–1.38) 0.46
0.54 (0.26–1.09) 0.08 2.15 (1.22–3.80) 0.01 1.11 (0.44–2.77) 0.83
1.61 (1.28–2.02) 0.00005 0.95 (0.70–1.28) 0.73 0.81 (0.55–1.18) 0.27
0.34 (0.15–0.75) 0.01 1.31 (0.76–2.29) 0.33 0.75 (0.26–2.15) 0.59
0.84 (0.68–1.04) 0.10 1.25 (0.99–1.59) 0.06 0.89 (0.68–1.17) 0.41
0.78 (0.49–1.22) 0.27 1.57 (1.09–2.27) 0.02 0.60 (0.31–1.17) 0.13
0.86 (0.69–1.08) 0.19 1.29 (1.02–1.64) 0.04 0.97 (0.73–1.31) 0.86
1.17 (0.96–1.43) 0.13 0.82 (0.64–1.04) 0.10 0.95 (0.72–1.26) 0.73
1.86 (1.19–2.91) 0.01 0.49 (0.17–1.40) 0.19 0.69 (0.27–1.78) 0.45
2.41 (1.08–5.37) 0.03 0.23 (0.03–1.62) 0.14 0.68 (0.17–2.71) 0.58
1.14 (0.95–1.37) 0.15 0.84 (0.69–1.02) 0.08 1.14 (0.90–1.44) 0.27
1.17 (0.85–1.62) 0.34 0.66 (0.43–1.02) 0.06 1.13 (0.72–1.78) 0.59
0.47 (0.23–0.96) 0.04 1.21 (0.73–1.99) 0.46 1.36 (0.77–2.38) 0.29
0.99 (0.77–1.27) 0.91 1.45 (1.12–1.88) 0.004 0.82 (0.58–1.17) 0.27
1.22 (1.01–1.46) 0.04 0.89 (0.71–1.13) 0.34 1.24 (0.97–1.59) 0.09
0.65 (0.20–2.13) 0.48 3.70 (1.56–8.80) 0.003 0.59 (0.08–4.45) 0.61
0.60 (0.27–1.33) 0.20 2.29 (1.10–4.76) 0.03 1.07 (0.44–2.65) 0.88
0.58 (0.33–1.03) 0.06 1.42 (0.85–2.36) 0.18 1.56 (0.87–2.81) 0.14
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SNPs in this region could be capturing variants in other
nearby genes: for instance, immediately upstream of
SLC22A1 and SLC22A2 in chromosome 6 lies the gene
encoding the insulin-like growth factor 2 receptor
(IGF2R), an excellent biological candidate.
This study constitutes the ﬁrst large-scale prospective
pharmacogenetic evaluation of metformin action in a
controlled clinical trial. The UK Prospective Diabetes
Study (29) and A Diabetes Outcome Progression Trial
(ADOPT) (30) investigators independently showed that a
substantial proportion of patients with type 2 diabetes
eventually fail metformin therapy, deﬁned by a need for
additional pharmacotherapy to control hyperglycemia.
Given the higher prior probability afforded by the known
biological role of SLC47A1 in disposing of metformin and
the previously reported genetic association of the major
allele at SNP rs2289669 with poorer metformin response
(5), validation in the DPP can be convincing without
achieving the levels of statistical signiﬁcance required for
novel ﬁndings. Our index SNP (rs8065082) is in tight LD
with rs2289669 (r
2 
0.8 in HapMap CEU) and the direction
of effect is consistent in DPP, a cohort nearly 10-fold larger
than the one documented in the original report from
Rotterdam (5). Thus, our ﬁndings conﬁrm those of Becker
et al. (5) and suggest that major allele homozygotes at this
locus (
30% of the European population) may experience
suboptimal responses to metformin treatment.
Our ﬁndings on the SLC22A1 locus and metformin
response are less robust. While our noted association
with a missense SNP appears compelling, it is not
among the most functional human variants described by
Shu et al. (3), and it is in weak LD with rs622342 (r
2

0.14 in HapMap CEU), a SLC22A1 SNP associated
with metformin response in another report from Rotter-
dam (31). SNP rs622342 was included among our tag
SNPs but showed no evidence of an interaction with
metformin (nominal P  0.69) or an effect on diabetes
incidence in any arm, raising the possibility that the
original ﬁnding may have been spurious. Similarly, the
SLC22A2 missense SNP rs316019 (A270S), reported to
inﬂuence metformin renal excretion and affect its
plasma concentrations (32), did not signiﬁcantly inter-
act with metformin in the DPP (nominal P  0.35). Our
novel ﬁndings in the putative metformin drug targets
STK11 and AMPK require conﬁrmation, as do those in
MEF2A and MEF2D, themselves regulated by AMPK
(33). One of the most signiﬁcant interactions with
metformin occurred at an SNP in HNF4A; given its role
in hepatic gluconeogenesis (34), this intriguing result
deserves further exploration. In contrast, the multiple
interactions noted in the ABCC8-KCNJ11 locus re-
ported previously (35) do not offer a clear mechanism of
action. Finally, nominal associations with response to
lifestyle modiﬁcation should be replicated in cohorts
that underwent a similar intervention.
In summary, we have conducted a large-scale genetic
association study in the DPP and replicated the associ-
ation of a polymorphism in a metformin transporter
with metformin response. Other hypothesis-generating
results require more detailed characterization in the
DPP and follow-up in independent samples. A focus on
likely functional variants may uncover loci with stron-
ger effects.
TABLE 5
Candidate gene variants showing a nominally signiﬁcant interaction with the lifestyle intervention in the DPP
SNP Chromosome
Position
(NCBI 36) Gene
Alleles
(m/M)
Interaction genotype * lifestyle
Observed
P
Permuted
P FDR Q
rs3792269 2 241180152 CAPN10 G/A 0.005 0.008 0.84
rs2425640 20 42461451 HNF4A A/G 0.01 0.01 0.84
rs1342514 1 56959948 PRKAA2 G/C 0.01 0.005 0.84
rs4725408 7 150881542 PRKAG2 C/T 0.02 0.005 0.84
rs7599142 2 162701737 GCG A/G 0.02 0.01 0.84
rs17367421 1 153553865 PKLR C/G 0.02 0.01 0.84
rs12374408 4 23463581 PPARGC1A T/C 0.02 0.03 0.84
rs3751151 12 119926582 HNF1A T/A 0.02 0.02 0.84
rs11024298 11 17448407 ABCC8 T/G 0.02 0.01 0.84
rs6008306 22 45018756 PPARA T/C 0.02 0.01 0.84
rs1422429 5 149146627 PPARGC1B A/G 0.02 0.02 0.84
rs1054442 12 47675587 PRKAG1 C/A 0.03 0.02 0.84
rs9965495 18 56184656 MC4R T/C 0.03 0.02 0.84
rs1008284 17 33136571 HNF1B T/C 0.03 0.03 0.84
rs2018675 17 19382123 SLC47A1 T/C 0.03 0.02 0.84
rs8032587 15 98068933 MEF2A C/T 0.03 0.02 0.84
rs7626560 3 12450088 PPARG A/G 0.04 0.04 0.84
rs17161829 7 99187763 CYP3A4 A/G 0.04 0.01 0.84
rs6701920 1 159181541 ITLN2 A/G 0.04 0.02 0.84
rs461473 6 160463552 SLC22A1 T/C 0.04 0.04 0.84
rs17159890 1 145094998 PRKAB2 C/A 0.046 0.05 0.84
rs11904814 2 208135043 CREB1 C/A 0.046 0.05 0.84
rs17373414 3 188068221 ADIPOQ T/C 0.049 0.06 0.84
SNPs in or near biological candidate genes showing a nominally signiﬁcant interaction with the lifestyle intervention in the DPP are shown.
HRs are estimated for the minor allele (m) vs. the major allele (M) under an additive genetic model. Only the top SNP within each gene region
is shown; the full set of results (including allele frequencies) is available in supplementary Table 2.
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